Targeting KRAS-mutant stomach/colorectal tumors by disrupting the ERK2-p53 complex
Xiang Wang(University of Science and Technology of China), Jing‐Yu Lang(The University of Texas MD Anderson Cancer Center), Qing Xie(Nanchang University), Jiaxin Yang(Shanghai Institute of Nutrition and Health), Fangfei Peng(Shanghai Institute of Nutrition and Health), Feng Jiang(Northwestern Polytechnical University), Dandan Liu(Kunming Medical University), Yongfeng Zhang(Jilin University), Chen Qing(Kunming Medical University), Leizhen Zheng(Shanghai Jiao Tong University), Wenzhe Ma(Macau University of Science and Technology), Xiangyin Kong(Shanghai Institute of Nutrition and Health), Jiayan Shen(Hangzhou Normal University)
Cited by 11
Related Papers
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
PKM2 and cancer: The function of PKM2 beyond glycolysis
|Oncology Letters|2016|335
FUNDC1 protects against doxorubicin-induced cardiomyocyte PANoptosis through stabilizing mtDNA via interaction with TUFM
|Cell Death and Disease|2022|139
APOBEC3G promotes liver metastasis in an orthotopic mouse model of colorectal cancer and predicts human hepatic metastasis
|Journal of Clinical Investigation|2011|132